BeCoMe-9: a Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B
Latest Information Update: 20 Mar 2025
At a glance
- Drugs BE 101 (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man
- Acronyms BeCoMe-9
- Sponsors Be Biopharma
- 18 Feb 2025 Planned End Date changed from 1 May 2027 to 1 Jul 2027.
- 18 Feb 2025 Planned primary completion date changed from 1 May 2027 to 1 Jul 2027.
- 15 Jan 2025 According to a Be Biopharma media release, company announced the closing of its $92M Series C financing and the proceeds from the Series C financing will be used to generate clinical proof-of-concept for BE-101 in the ongoing BeCoMe-9 Phase 1/2 clinical trial for people with hemophilia B and to advance BE-102 for the treatment of hypophosphatasia to the clinic.